跳至主要内容
临床试验/ACTRN12622000787785
ACTRN12622000787785已完成未知

Prognostic role of immune environment in luminal B early breast cancer

Breast Cancer Research Centre - WA0 个研究点目标入组 120 人开始时间: 2022年6月2日最近更新:
适应症

试验速览

阶段
未知
状态
已完成
发起方
入组人数
120

研究概览

简要总结

暂无简介。

研究设计

研究类型
Observational

入排标准

年龄范围
44 Years 至 55 Years(—)
性别
All

入选标准

  • Patients with Stage I, II and III breast cancer managed by the Principal Investigator between January 2000 to June 2013
  • Luminal B disease
  • Patient aged between 45 - 55 years of age at time of diagnosis
  • Adequate tissue from primary breast tissue and axillary node for evaluation
  • Follow-up for minimum of 12 months from diagnosis

排除标准

  • Patient lost to follow-up prior to 12 months
  • Patient non-compliant with recommended local or systemic adjuvant therapy
  • Luminal A breast cancer as defined as any histological type invasive carcinoma which is grade 1 and HER2 negative
  • Contralateral breast cancer in the absence of loco-regional relapse and/or metastatic relapse will not be regarded as a breast cancer event
  • .Comorbidities which may be associated with altered immune function: rheumatoid arthritis, autoimmune illness, HIV-associated illness.
  • Other malignancies with the exception of non-melanomatous skin cancer, which were managed by surgical excision or topical cryotherapy in the past
  • Previous exposure to cytotoxic or immunotherapy.
  • Previous radiation therapy

研究者

发起方
Breast Cancer Research Centre - WA

相似试验

Prognostic role of immune environment in luminal B... | 临床试验